Humanigen’s stock tumbles 67% after sharing new clinical data for its COVID-19 treatment

Shares of Humanigen Inc. HGEN, -80.10% plunged 67.9% in premarket trading on Wednesday, the day after the company said a National Institutes of Health clinical trial testing lenzilumab and Gilead Scie...